	US 12,268,712 B2
	Pharmaceutical composition for postpartum recovery and treatment of pelvic floor dysfunction
Peter Takacs, Norfolk, VA (US)
Assigned to Fempharma Europe, LLC, Budapest (HU)
Appl. No. 17/283,241
Filed by Fempharma Europe, LLC, Budapest (HU)
PCT Filed Oct. 4, 2019, PCT No. PCT/IB2019/001065 § 371(c)(1), (2) Date Apr. 6, 2021, PCT Pub. No. WO2020/074952, PCT Pub. Date Apr. 16, 2020.
Claims priority of provisional application 62/742,404, filed on Oct. 7, 2018.
Prior Publication US 2021/0346427 A1, Nov. 11, 2021
Int. Cl. A61K 33/30 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/202 (2006.01); A61K 45/06 (2006.01); A61P 15/00 (2006.01); A61P 21/00 (2006.01)

CPC A61K 33/30 (2013.01) [A61K 9/0053 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 45/06 (2013.01); A61P 15/00 (2018.01)]

15 Claims

1. A method of promoting recovery of pelvic floor muscles in a postpartum female subject, the method comprising administering to the subject a pharmaceutical composition comprising zinc, leucine, and omega-3 fatty acids, wherein the composition is formulated for oral delivery, and wherein administration commences within about 48 hours of vaginal delivery by the subject and continues daily for at least about four weeks.